139 related articles for article (PubMed ID: 2822425)
21. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer.
Xie Y; Zhang Y; Du L; Jiang X; Yan S; Duan W; Li J; Zhan Y; Wang L; Zhang S; Li S; Wang L; Xu S; Wang C
Mol Oncol; 2018 May; 12(5):648-658. PubMed ID: 29504701
[TBL] [Abstract][Full Text] [Related]
22. Detection and significance of serum protein markers of small-cell lung cancer.
Han M; Liu Q; Yu J; Zheng S
J Clin Lab Anal; 2008; 22(2):131-7. PubMed ID: 18348318
[TBL] [Abstract][Full Text] [Related]
23. Detection of serum p53 protein in lung cancer patients.
Luo JC; Zehab R; Anttila S; Ridanpaa M; Husgafvel-Pursiainen K; Vainio H; Carney W; De Vivo I; Milling C; Brandt-Rauf PW
J Occup Med; 1994 Feb; 36(2):155-60. PubMed ID: 8176513
[TBL] [Abstract][Full Text] [Related]
24. c-erbB-2 protein in serum of primary lung cancer patients.
Filiberti R; Marroni P; Paganuzzi M; Izzo V; Padovani P; Cafferata M; Ardizzoni A; Neri M; Raimondi L; Puntoni R
Cancer Detect Prev; 2002; 26(1):64-8. PubMed ID: 12088205
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), enolase (NSE) and thymidine-kinase (TK) in the monitoring and prognosis of primary carcinoma of the lung].
De Angelis G; De Marinis F; Bigioni D; Migliorino MR; Alma MG; Pigorini F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):135-40. PubMed ID: 1965445
[No Abstract] [Full Text] [Related]
26. Neuron-specific enolase and lung cancer.
Karnak D; Beder S; Kayacan O; Ibiş E; Oflaz G
Am J Clin Oncol; 2005 Dec; 28(6):586-90. PubMed ID: 16317269
[TBL] [Abstract][Full Text] [Related]
27. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
28. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
30. Serum angiopoietin-2 as a clinical marker for lung cancer.
Park JH; Park KJ; Kim YS; Sheen SS; Lee KS; Lee HN; Oh YJ; Hwang SC
Chest; 2007 Jul; 132(1):200-6. PubMed ID: 17505039
[TBL] [Abstract][Full Text] [Related]
31. Cut-off levels of NSE to differentiate SCLC from NSCLC.
Satoh H; Ishikawa H; Kurishima K; Yamashita YT; Ohtsuka M; Sekizawa K
Oncol Rep; 2002; 9(3):581-3. PubMed ID: 11956631
[TBL] [Abstract][Full Text] [Related]
32. Factors confounding evaluation of treatment effect in lung cancer.
Osterlind K
Lung Cancer; 1994 Mar; 10 Suppl 1():S97-103. PubMed ID: 8087532
[TBL] [Abstract][Full Text] [Related]
33. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
Oremek GM; Sapoutzis N
Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
[TBL] [Abstract][Full Text] [Related]
34. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
36. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in patients with non-small cell lung cancer after surgery.
Ju X; Zheng L; Niu Y; Guan H; Luo H
Asian J Surg; 2020 Sep; 43(9):940-941. PubMed ID: 32522378
[No Abstract] [Full Text] [Related]
37. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer.
Isbell JM; Jones DR; Li BT
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2628-2631. PubMed ID: 29615336
[No Abstract] [Full Text] [Related]
39. Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis.
Lombardi C; Tassi GF; Pizzocolo G; Donato F
Chest; 1990 Mar; 97(3):639-44. PubMed ID: 1689630
[TBL] [Abstract][Full Text] [Related]
40. Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer.
Nutini S; Cappelli G; Benucci A; Catalani C; Nozzoli F
Int J Biol Markers; 1990; 5(4):198-202. PubMed ID: 1965544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
